Last reviewed · How we verify

Ischemic priapism — Treatment Landscape & Competitive Intelligence

Ischemic priapism (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Ischemic priapism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Plenaxis ABARELIX Speciality European abarelix Gonadotropin-releasing hormone receptor 2003-01-01
Plenaxis Plenaxis PRAECIS Pharmaceuticals Inc. Gonadotropin-releasing hormone receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. PRAECIS Pharmaceuticals Inc. · 1 drug in Ischemic priapism
  2. Speciality European · 1 drug in Ischemic priapism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Ischemic priapism:

Cite this brief

Drug Landscape (2026). Ischemic priapism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ischemic-priapism. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing